Kiteva Trenchevska, Gordana

Preferred name

Official Name

Kiteva Trenchevska, Gordana

Main Affiliation

gordana.kiteva.trenchevska@medf.ukim.edu.mk

Now showing 1 - 10 of 33

Some of the metrics are blocked by your
consent settings
Development and validation of a bioanalytical LC-UV method with solid-phase extraction for determination of valproic acid in saliva.
(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2012-06)
;
Haxhiu, Arlinda
;
;
;
A bioanalytical HPLC method with UV detection for the determination of the antiepileptic drug valproic acid in human saliva has been developed and validated. Saliva represents an alternative matrix for therapeutic monitoring of antiepileptic drugs due to the increasing interest in free drug concentration. The proposed method involved solid-phase extraction for sample preparation and yielded very good mean recoveries of 99.4 % and 97.9 % for valproic acid and IS, respectively. The calibration function for valproic acid was linear over the concentration range of 1.0-50.0 μg mL⁻¹ (R² = 0.9989). Within-run and between-run precision and accuracy were studied at four concentrations and RSDs were less than 7.3 and 2.2 %, while accuracy values were higher than 96.8 and 97.5 %, respectively. The described method provides sensitivity, linearity, precision, accuracy and is suitable for analyses of valproic acid in saliva samples.
Some of the metrics are blocked by your
consent settings
Intracerebral Hematoma, Perihemorrhagic Edema and Urinary Excreted Cysteinyl Leukotrienes Correlation Study
(Walter de Gruyter GmbH, 2014-08-01)
;
Nikodijevic, Dijana
;
;
;
<jats:title>Abstract</jats:title><jats:p><jats:bold>Introduction.</jats:bold>Several mechanisms in formation of perihemorrhagic edema are activated after contact of brain tissue-extravasated blood in intracerebral hemorrhage. Cysteinyl leukotrienes (cysLT) (C4, D4, E4) are included in this process as significant edema factors and they determine the neurological deficit and outcome. The study aim was a 5-day follow-up (admission/3 day/5 day) of urinary cysLT, hematoma volume, edema volume values and their correlation in patients after spontaneous, primary supratentorial intracerebral hemorrhage.</jats:p><jats:p><jats:bold>Methods.</jats:bold>An enzyme immunoassay was used for urinary cysLT measured in 62 patients and 80 healthy controls. Hematoma and edema volumes were visualized and measured by computed tomography and mathematically calculated with a special spheroid shape formula (V=AxBxC/2).</jats:p><jats:p><jats:bold>Results.</jats:bold>CysLT of hemorrhagic patients (1842.20±1413.2, 1181.54±906.2, 982.30±774.2pg/ml/mg creatinine) were significantly excreted (p<0.01). Brain edema (12.86±13.5, 22.38±21.1, 28.45±29.4cm<jats:sup>3</jats:sup>) was significantly increased (p<0.01). Hematoma volume values (13.05±14.5, 13.13±14.7, 12.99±14.7cm<jats:sup>3</jats:sup>) were not significant (p>0.05). A high correlation (multiple regression) between cysLT, hematoma and edema was found on the 3<jats:sup>rd</jats:sup>day (R=0.6) and a moderate correlation at admission (R=0.3) and on the 5<jats:sup>th</jats:sup>day (R=0.3).</jats:p><jats:p><jats:bold>Conclusion.</jats:bold>In our 5-day follow-up study a significant cysLT brain synthesis and significant brain edema progression versus constant hematoma volume values in hemorrhagic patients was found. A high correlation between cysLT, hematoma and edema volume was found on the 3<jats:sup>rd</jats:sup>day, a moderate correlation on admission and on the 5<jats:sup>th</jats:sup>day, which means that high cysLT and hematoma values were associated with high/moderate edema values.</jats:p>
Some of the metrics are blocked by your
consent settings
Risk factors associated with new-onset epilepsy in young adults: Population-based study
(Elsevier BV, 2021-10-19)
Babunovska, Marija
;
Boskovski, Bojan
;
Kuzmanovski, I
;
;
Risk factors for childhood and late-onset epilepsy are thoroughly described in existing literature, while they are less defined and ambiguous for young adults. We aimed to evaluate the prevalence of various risk factors associated with new-onset epilepsy in adults aged 20-49 years. We included all incident cases in North Macedonia between 2015 and 2018.
Some of the metrics are blocked by your
consent settings
Incidence and prevalence of epilepsy in the Republic of North Macedonia: Data from nationwide integrated health care platform
(Elsevier BV, 2021-03-04)
Babunovska, Marija
;
Boskovski, Bojan
;
Kuzmanovski, I
;
;
This study aimed to evaluate the incidence and period prevalence of epilepsy in the Republic of North Macedonia, an upper-middle-income country with universal access to healthcare, based on a nationwide healthcare platform (NHP).
Some of the metrics are blocked by your
consent settings
КОСКЕНИОТ КАНАЛ НА КОХЛЕАРНИОТ НЕРВ (BCNC) КАЈ ДЕЦА СО БИЛАТЕРАЛНИ ТЕШКО СЕНЗОНЕВРАЛНО ОШТЕТУВАЊЕ НА СЛУХОТ - КАРАКТЕРИСТИКИ И ЗНАЧЕЊЕ
(SHMSHM/AAMD, 2021-08-30)
М. Докоска
;
С. Николова
;
;
Цели: Цел на оваа ретроспективно аналитичка студија е одредување на вариациите на ширината од коскениот канал од кохлеарниот нерв кај пациенти со билатерално, тешко сензоневрално оштетување на слухот, која е корисна информација во предоперативната евалуација на децата кандидати за кохлеарна имплантација. Материјали и методи: Во оваа студија ретроспективно беа евалуираи КТ на 11 деца на возраст од 2-12 години, со билатерално тешко сензоневрално оштетување на слухот ,на кои во периодот Јули - Декември 2019 година на Универзитетската клиника за уво, нос и грло во Скопје им беше вграден кохлеарен имплант. Аксијалните пресеци од нивните КТ снимки беа користени за мерење на ширината на коскениот канал од кохлеарниот нерв. Резултати: Од добиените резултати просечната вредност на ширината на BCNC кај нашата група на пациенти изнесува 1.5± 0.3мм, минимум 1.0 мм, максимум 2.3мм. Заклучок: Вредностите за ширината на BCNC се движат во широки граници и дополнителни истражувања се потребни за нивна спореба со вредностите кај пациенти кои имаат нормален слух.
Some of the metrics are blocked by your
consent settings
Outcome predictors of post-COVID conditions in the European Academy of Neurology COVID-19 registry.
(Springer science + Business Media, 2024-06)
Leone MA
;
Helbok R
;
Bianchi E
;
Yasuda CL
;
Konti M
Several neurological manifestations are part of the post-COVID condition. We aimed to: (1) evaluate the 6-month outcome in the cohort of patients with neurological manifestations during the COVID-19 acute phase and surviving the infection, and find outcome predictors; (2) define the prevalence and type of neurological symptoms persistent at six months after the infection. Data source was an international registry of patients with COVID-19 infection and neurological symptoms, signs or diagnoses established by the European Academy of Neurology. Functional status at six-month follow-up was measured with the modified Rankin scale (mRS), and defined as: "stable/improved" if the mRS at six months was equal as or lower than the baseline score; "worse" if it was higher than the baseline score. By October 30, 2022, 1,003 lab-confirmed COVID-19 patients were followed up for a median of 6.5 months. Compared to their pre-morbid status, 522 patients (52%) were stable/improved, whereas 465 (46%) were worse (functional status missing for 16). Age, hospitalization, several pre-COVID-19 comorbidities, and COVID-19 general complications were predictors of a worse status. Amongst neurological manifestations, stroke carried the highest risk for worse outcome (OR 5.96), followed by hyperactive delirium (2.8), and peripheral neuropathies (2.37). On the other hand, hyposmia/hypogeusia (0.38), headache (0.40), myalgia (0.45), and COVID-19 vaccination (0.52) were predictors of a favourable prognosis. Persisting neurological symptoms or signs were reported by 316/1003 patients (31.5%), the commonest being fatigue (n = 133), and impaired memory or concentration (n = 103). Our study identified significant long-term prognostic predictors in patients with COVID-19 and neurological manifestations.
Some of the metrics are blocked by your
consent settings
Phenotypic spectrum in families with mesial temporal lobe epilepsy probands
(Elsevier BV, 2018-05)
;
Igor Kuzmanovski
;
Marija Babunovska
;
Bojan Boshkovski
;
Tatjana Cepreganova Cangovska
The traditional perception of mesial temporal lobe epilepsy (MTLE) as a predominantly acquired disorder is challenged due to emerging evidence of familial aggregation. In this study, we ascertained the extent of familial occurrence of epilepsy in MTLE patients, as well as phenotypic heterogeneity in affected relatives.
Some of the metrics are blocked by your
consent settings
Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy.
(American Medical Association, 2024-05)
Battino D
;
Tomson T
;
Bonizzoni E
;
Craig J
;
Perucca E
Importance: Women with epilepsy (WWE) require treatment with antiseizure medications (ASMs) during pregnancy, which may be associated with an increased risk of major congenital malformations (MCMs) in their offspring. Objective: To investigate the prevalence of MCMs after prenatal exposure to 8 commonly used ASM monotherapies and changes in MCM prevalence over time. Design, setting, and participants: This was a prospective, observational, longitudinal cohort study conducted from June 1999 to October 2022. Since 1999, physicians from more than 40 countries enrolled ASM-treated WWE before pregnancy outcome was known and followed up their offspring until 1 year after birth. Participants aged 14 to 55 years who were exposed to 8 of the most frequently used ASMs during pregnancy were included in this study. Data were analyzed from April to September 2023. Exposure: Maternal use of ASMs at conception. Main outcomes and measures: MCMs were assessed 1 year after birth by a committee blinded to type of exposure. Teratogenic outcomes across exposures were compared by random-effects logistic regression adjusting for potential confounders and prognostic factors. Results: A total of 10 121 prospective pregnancies exposed to ASM monotherapy met eligibility criteria. Of those, 9840 were exposed to the 8 most frequently used ASMs. The 9840 pregnancies occurred in 8483 women (mean [range] age, 30.1 [14.1-55.2] years). MCMs occurred in 153 of 1549 pregnancies for valproate (9.9%; 95% CI, 8.5%-11.5%), 9 of 142 for phenytoin (6.3%; 95% CI, 3.4%-11.6%), 21 of 338 for phenobarbital (6.2%; 95% CI, 4.1%-9.3%), 121 of 2255 for carbamazepine (5.4%; 95% CI, 4.5%-6.4%), 10 of 204 for topiramate (4.9%; 95% CI, 2.7%-8.8%), 110 of 3584 for lamotrigine (3.1%; 95% CI, 2.5%-3.7%), 13 of 443 for oxcarbazepine (2.9%; 95% CI, 1.7%-5.0%), and 33 of 1325 for levetiracetam (2.5%; 95% CI, 1.8%-3.5%). For valproate, phenobarbital, and carbamazepine, there was a significant increase in the prevalence of MCMs associated with increasing dose of the ASM. Overall prevalence of MCMs decreased from 6.1% (153 of 2505) during the period 1998 to 2004 to 3.7% (76 of 2054) during the period 2015 to 2022. This decrease over time was significant in univariable logistic analysis but not after adjustment for changes in ASM exposure pattern. Conclusions and relevance: Of all ASMs with meaningful data, the lowest prevalence of MCMs was observed in offspring exposed to levetiracetam, oxcarbazepine, and lamotrigine. Prevalence of MCMs was higher with phenytoin, valproate, carbamazepine, and phenobarbital, and dose dependent for the latter 3 ASMs. The shift in exposure pattern over time with a declining exposure to valproate and carbamazepine and greater use of lamotrigine and levetiracetam was associated with a 39% decline in prevalence of MCMs, a finding that has major public health implications.
Some of the metrics are blocked by your
consent settings
Prevalence of various risk factors associated with new-onset epilepsy after the age of 50: a retrospective population-based study
(Wiley, 2022-02-01)
;
Babunovska, Marija
;
Boskovski, Bojan
;
Kuzmanovski, I
;
Population-based studies of epilepsy risk factors are rare. We aimed to evaluate the prevalence of various risk factors associated with new-onset epilepsy after the age of 50 years. We included all incident cases in North Macedonia between 2015 and 2018. Study participants were ascertained from the national healthcare platform. We performed a retrospective analysis of Electronic Health Records of 2,367 patients (1,017 females and 1,350 males) whose epileptic seizures started after the age of 50 years. Patients were stratified into 10-year age groups. The most common risk factor for new-onset epilepsy in our cohort was stroke, which was associated with new-onset epilepsy in 20% of patients aged 50-59 years and almost 50% of patients aged 70-79 years. The second most frequent risk factor was neoplasm in patients aged 50-69 years and dementia in patients older than 70 years. The other pre-existing conditions included: metabolic disorders, traumatic brain injury, and postencephalitic and inflammatory diseases. Chronic alcoholism was the most common metabolic risk factor associated with new-onset epilepsy and accounted for 84% of cases in this subgroup. Only metabolic disorders were significantly more frequent in males than in females (p<0.00001). We did not identify any epilepsy risk factor in 967 patients (41%). Systemic vascular risk factors were frequent in our cohort: 1,574 patients had hypertension (66%) and 449 patients had diabetes (19%), and 339 had both conditions (14%). We found that structural lesions were the most prevalent risk factor associated with new-onset epilepsy in middle-aged and elderly patients. Recognition of possibly modifiable factors associated with late-onset epilepsy could have a positive impact on reducing the risk of developing epilepsy.
Some of the metrics are blocked by your
consent settings
Micturition and startle-induced reflex seizures in a patient with focal cortical dysplasia in the middle frontal gyrus
(Elsevier BV, 2019)
;
Marija Babunovska
;
I Kuzmanovski
;
Bojan Boskovski
;

Kiteva Trenchevska, Gordana

Filters

Settings

Sort By

Results per page